Androgenetic Alopecia: Therapy Update

Area of Science:

• Dermatology
• Trichology
• Pharmacology

Background:

• Androgenetic alopecia (AGA), encompassing male and female pattern hair loss, is the most prevalent global alopecia.
• It results from an exaggerated androgen response and presents distinct patterns in men and women.
• AGA is a chronic condition influenced by genetic and environmental factors, posing treatment challenges.

Purpose of the Study:

• To provide a comprehensive review of Androgenetic alopecia (AGA) treatments.
• To evaluate existing, alternative, and emerging therapeutic options for AGA.
• To analyze the mechanisms of action, costs, efficacies, and safety profiles of various AGA treatments.

Main Methods:

• Literature review of scientific studies on AGA treatments.
• Analysis of FDA-approved medications (minoxidil, finasteride).
• Evaluation of non-FDA-approved and novel therapeutic approaches for AGA.

Main Results:

• Only two FDA-approved drugs exist for AGA: topical minoxidil and oral finasteride.
• Numerous non-FDA-approved treatments demonstrate efficacy in studies.
• Emerging therapies require further exploration for AGA treatment.

Conclusions:

• AGA treatment remains challenging despite available options.
• A review of current and novel therapies is crucial for effective AGA management.
• Further research into alternative and upcoming treatments is needed to address AGA comprehensively.